Article Abstract

Pros: Can tissue biopsy be replaced by liquid biopsy?

Authors: Marius Ilié, Paul Hofman

Abstract

In the past decade, ‘personalized’ or ‘stratified’ management based on the molecular features of tumors of patients with advanced non-small-cell lung cancer (NSCLC) has entered routine clinical practice. Identification on tumor tissue of predictive biomarkers of response to targeted treatments is now mandatory for optimal patient care, but faces several biological and technological challenges.